Active Ingredient History
TRIETHYLENEMELAMINE, an aziridine derivative, is an alkylating agent with antineoplastic properties. Formerly it was used in the palliative treatment of the lymphomas and leukemias. Now it is used as a research tool to produce chromosome aberrations and cancers. NCATS
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Neoplasms (approved 1954)
Ovarian Neoplasms (approved 1990)
Lymphoma (Phase 1)
Neuralgia, Postherpetic (Phase 2)
Sarcoma (Phase 1)
Urinary Bladder, Overactive (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue